Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention comprises a number of aspects .
• a 5 use of a new medicinal product for the treatment and/or prevention of amyloidos-related diseases is disclosed .
• a use of a food stuff or food supplement for the treatment and/or prevention of amyloidos-related diseases is 0 disclosed .
• a method of for the treatment and/or prevention of amyloidos-related diseases is disclosed .
• a method for treatment and/or prevention of 5 Alzheimer' s disease is disclosed .
• a fatty acid composition comprising at least ( all-Z omega-3) - 4 , 7 , 10 , 13 , 16 , 19-docosahexaenoic acid ( DHA)
• a fatty acid composition comprising a combination of (all-Z 0 omega-3 ) -5 , 8 , 11, 14 , 17-eicosapentaenoic acid (EPA) , and ( all-Z omega-3 ) -4 , 7 , 10 , 13 , 16 , 19-docosahexaenoic acid ( DHA) .
• the fibrils of the amyloid in which they are found in the disease states are extremely similar in their overall appearance .
• Proteins known to have the propensity of fibrillar conformation in humans called precursor proteins , are making up a list of 21 exponents (3 ) and the number is increasing .
• the protein in the fibril is made up of a small number of amino acids on average around 20-60 grouping them in the category of polypeptides rather than proteins .
• Proteins are usually made up of an alfa-helix and a beta-sheet .
• Amyloid fibrils usually contain beta-sheet material only rendering the molecules physical properties different from the parent protein . While normal proteins are subj ected to a continuous process of degradation by proteolysis , one very important feature of fibrils is the ability, once formed, to be essentially indestructible under physiological conditions . The amyloid fibrils are dominated by hydrogen bonding between the amid and the carbonyl groups of the main chain, rather than by specific interactions of the side chains , which determine the structure of normal proteins .
• beta-sheets This abnormal bonding induced by the large number of hydrogen bonds of the beta-sheet that must be disrupted to rescue the polypeptide chain from the aggregated state, results in a high resistance to degradation and properly removal from the tissue of deposition . While in alfa-helices the hydrogen bonds are between side groups within the same strand, in beta sheets the bonds are between one strand and another . Since the second beta-strand can come from a different region of the same protein or from a different molecule, formation of beta-sheets is usually stabilised by protein oligomerisation or aggregation . In this manner the misfolded protein self-associates and become deposited in amyloid aggregates in diverse organs , inducing tissue damage and organ dysfunction .
• the number of non-covalent interactions is to some degree a function of the protein chain length meaning that splicing of a section of the protein to a peptide will render the peptide with less stability due to the lower number of non-covalent interactions .
• the normal folding forces will be weaker which could favour the formation of fibrils .
• fatty acids (5) Less known but significantly important for normal folding as well as maintenance of a stable three- dimensional structure, is protein acylation by covalent attachment of fatty acids (5) . It is well established that the protein albumin is able to bind several molecules of fatty acids . Saturated fatty acids such as stearic, palmitic and myristic acid are the predominant fatty acids that attach to proteins in eukaryotic cells ( 6) . From studies using radiolabelled fatty acids we know that each fatty acid labels a different sub-population of proteins with the fatty acid interacting with basic amino acids such as lysine, glycine and arginin . The carboxyl group of the fatty acid forms a salt bridge or a hydrogen bond with basic amino acid side chains . All sites have cylindrical hydrophobic channels of varying shape that force the saturated fatty acids to assume a nearly linear configuration . However, the binding pockets are large enough to accommodate unsaturated fatty acids such as oleic acid and arachidonic acid (7 )
• amyloid also contains a certain amount of fatty acids .
• methanol extraction of amyloid derived from transthyretin about 10% of the dry mass was soluble pointing to the presence of a lipid fraction ( 8 ) .
• Gas-chromatography revealed the presence of mixtures of saturated fatty acids like those mentioned above, but also to polyunsaturated fatty acids like palmitoleic acid, linoleic acid, alfa-linolenic acid and arachidonic acid .
• This pattern of fatty acids is typical for a modern Western diet, which is very much based on saturated fat from dairy products and meat together with seed derived oils . It is quite clear that fatty acids have a function in the normal folding of proteins .
• Amyloid deposits can be reabsorbed and organ function reversed if the synthesis of amyloidogenic protein is shut down . There seems to be a fine balance between the rate at which amyloid is formed and its clearance . It may therefore be possible to promote the resorption of amyloid by reducing the concentration of the amyloidogenic protein to a level below a critical threshold without necessarily eliminating the precursor (AA) .
• AA precursor
• Studies of the mechanism of conversion from normally soluble precursor proteins into amyloid fibrils have benefited from the fact that the transition can be reproduced under laboratory conditions . In vitro experiments have demonstrated that conversion of native , fully folded protein into a highly amyloidogenic, partially folded conformer could be blocked by stabilizing native proteins with a specific ligand ( 9 ) .
• a method for specific treatment of Alzheimer' s disease preferably due to prevention against fibril formation and/or reduction of deposed fibrils or plaques, known as amyloid .
• a fatty acid composition comprising at least (all-Z omega-3 ) -4 , 7 , 10, 13, 16, 19-docosahexaenoic acid (DHA) .
• a fatty acid composition comprising at least a combination of ( all-Z omega-3 ) -4 , 7 , 10 , 13 , 16, 19- docosahexaenoic acid (DHA) , and (all-Z omega-3 ) - 5 , 8 , 11 , 14 , 17-eicosapentaenoic acid (EPA) .
• the invention relates to the use of a fatty acid composition comprising at least ( all-Z omega-3 ) -4 , 7 , 10 , 13 , 16 , 19- docosahexaenoic acid (DHA) for the production of a medicinal product for the treatment and/or prevention of amyloidos-related diseases .
• DHA docosahexaenoic acid
• a fatty acid composition according to the invention predominantly containing DHA seemed to prevent and/or delay formation of fibrils most effectively, wherein DHA may act as an antagonist .
• a fatty acid composition containing at least a combination of the two fatty acids DHA and EPA also demonstrates preventive effect against fibril formation .
• the treatment according to the invention could be preventive reducing the propensity of fibril formation as well as therapeutic in situations with established amyloid .
• proteins or fragment of proteins are converted from their normally soluble forms to insoluble fibrils or plaques , which accumulate in a variety of organs including the liver, kidneys , spleen, brain, and internal secretory glands like the beta cells of the pancreas inducing toxic effects on cells and tissue .
• the final forms of these aggregates often have a well-defined pathological anatomical appearance, known as amyloid . This is the reason for the use of the term amyloidoses to describe many of the clinical conditions with which deposition of amyloid are associated .
• amyloidos-related diseases means clinical conditions or diseases with which deposition of amyloid, preferably as a consequence of fibril formation, are associated, such as for instance Alzheimer' s Dementia, type II diabetes , IgA nephropathy, kidney amyloidoses secondary to chronic inflammatory diseases and Parkinson' s disease .
• the fatty acid composition according to the invention further comprises (all-Z omega-3 ) -5 , 8 , 11 , 14 , 17-eicosapentaenoic acid (EPA) .
• EPA eicosapentaenoic acid
• the invention relates to the use of a fatty acid composition, wherein the weight ratio of EPA : DHA in the fatty acid composition is 1 : X, where X is equal or greater than 1. Please note that X being one of an integer or non-integer .
• a preferred effect of the invention is accomplished by a fatty acid composition rich in DHA.
• the term “rich” herein includes more or less a fatty acid composition primary containing DHA (none EPA) and a fatty acid composition where the amount of DHA > EPA .
• the term “amount” herein relates to weight or volume of the fatty acid composition .
• the desired pharmacological and/or therapeutic effect may be achieved by the fatty acid composition according to the invention .
• EPA and DHA in the fatty acid composition are present in the composition in an EPA: DHA ratio from 1 : 1 to 1 : 8. In a more preferred embodiment the EPA: DHA ratio in the fatty acid composition is from about 1 : 1 to 1 : 6. In a further embodiment of the invention, the fatty acid composition is a DHA-product .
• the fatty acids in the composition according to the invention is presented in at least one of esterified form, ethyl ester form, salt form and free acid form, or any combinations thereof .
• the fatty acid composition is comprised of a combination of EPA and DHA in triglyceride form.
• At least DHA is obtained from at least one of vegetable, microbial and animal origins, or combinations thereof .
• the fatty acid composition comprising at least a combination of DHA and EPA
• at least one of DHA and EPA is obtained from at least one of vegetable, microbial and animal origins or combinations thereof .
• the medicinal product or pharmaceutical product includes therefore for instance a fatty acid composition comprising at least one of a DHA-containing microbial oil and a mixture of an DHA-containing oil from microbial origin and a EPA-containing oil from a marine origin .
• the fatty acid composition according to the invention may additionally also comprise at least one of arachidonic acid (ARA) , docosapentaenoic acid, heneicosapentaenoic acid and octadecatentraenoic, or any combinations thereof .
• ARA arachidonic acid
• the EPA and/or DHA is produced from a marine oil, preferably a fish oil .
• the fatty acid composition is produced from a marine oil , such as a fish oil .
• the fatty acid composition is comprised of at least a combination of EPA and DHA in triglyceride form.
• the fatty acid composition is administered to a human or an animal , preferably orally .
• the medicinal product according to the invention may also be produced for administration though any other route where the active ingredients may be efficiently absorbed and utilized, e . g . intravenously, subcutaneously, intramuscularly, intranasally, rectally, vaginally or topically .
• said fatty acid composition is administered in an amount providing a daily dosage of 1 g to 15 g of said fatty acid composition for a human .
• a daily dosage of 1 g to 15 g of said fatty acid composition for a human In a preferred embodiment between 2 and 10 g of said fatty acid composition is administered per day, and in a more preferred embodiment between 2 and 8 g of said fatty acid composition .
• the medicinal product or pharmaceutical composition or pharmaceutical preparation according to the invention may also comprise other substances such as an inert vehicle, or pharmaceutical acceptable adj uvants , carriers , preservatives etc . , which are well known in to those skilled in the art .
• the medicinal product may also be administered to an animal, such as a pet or a horse .
• the medicinal product may be at least one of an amyloid- preventing agent or amyloid-deposit decreasing agent .
• the invention relates to a use of a fatty acid composition comprising at least (all-Z omega-3 ) -4 , 7 , 10 , 13 , 16 , 19-docosahexaenoic acid (DHA) that upon administration to a human or an animal will prevent the formation of aggregates of protein fibrils or plaque and/or reduce deposed fibrils , for the production of a medicinal product for the treatment and/or prevention of amyloidos-related diseases .
• DHA deposed fibrils
• said amyloidos-related disease is Alzheimer' s dementia .
• said amyloidos-related disease is IgA nephropathy .
• a fatty acid composition comprising a combination of at least DHA and EPA is used for the treatment and/or prevention of IgA nephropathy .
• the invention also includes use of a fatty acid composition comprising an effective amount of at least DHA or a combination of EPA or DHA that upon administration to a human or an animal preferable will prevent the formation of aggregates of protein fibrils or plaque and/or reduce deposed fibrils , for the production of a medicinal product for the treatment and/or prevention of IgA nephropathy .
• the invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3 ) -4 , 7 , 10, 13 , 16, 19-docosahexaenoic acid ( DHA) for the production of a medicinal product for the treatment and/or prevention of amyloidos-related diseases , wherein the disease is type II diabetes mellitus .
• said fatty acid composition further comprises (all-Z omega-3 ) - 5 , 8 , 11, 14 , 17-eicosapentaenoic acid (EPA) , i . e .
• the fatty acid composition comprising at least a combination of EPA and DHA for treatment of type II diabetes .
• the amount of DHA is > the amount of EPA.
• the amyloidos-related diseases is at least one of amyloidoses , Parkinson' s disease, amyotrophic lateral sclerosis , the spongiform encephalopathies such as Creutzfeld-Jacob disease , cystic fibrosis , kidney amyloidoses secondary to inflammatory diseases and renal amyloidoses, and amyloid deposition in myocardium and neural tissue .
• the present invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3 ) - 4 , 7 , 10 , 13 , 16 , 19-docosahexaenoic acid (DHA) for the production of a food stuff or food supplement for the treatment and/or prevention of amyloidos-related diseases .
• DHA deposed fibrils or plaques
• a fatty acid composition containing at least a combination of the two fatty acids DHA and EPA also demonstrates preventive effect against fibril formation .
• the treatment according to the invention could be preventive , reducing the propensity of fibril formation, as well as therapeutic in situations with established amyloid .
• the definition concerning "amyloidos-related" diseases is also included for the patent positions related to a food stuff or a food supplement according to the invention .
• One advantage of manufacturing and selling a food stuff for the treatment and/or prevention of amyloidos- related diseases is that such a food stuff will be more easily accessible for people .
• they preferably buy the product or supplement in a health store and/or a supermarket, and they do not need to visit a doctor .
• the present invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3 ) -4 , 7 , 10 , 13 , 16, 19-docosahexaenoic acid ( DHA) and (all-Z omega-3) -5 , 8 , 11 , 14 , 17- eicosapentaenoic acid (EPA) for the production of a food stuff or food supplement for the treatment and/or prevention of amyloidos-related diseases .
• DHA 19-docosahexaenoic acid
• EPA eicosapentaenoic acid
• the invention relates to the use of a fatty acid composition, wherein the weight ratio of EPA: DHA in the fatty acid composition is 1 : X, where X is equal or greater than 1. Please note that X being one of an integer or non- integer .
• a preferred effect of the invention concerning weight reduction is accomplished by a fatty acid composition rich in DHA.
• the term “rich” herein includes more or less a fatty acid composition primary containing DHA (none EPA) and a fatty acid composition where the amount of DHA > EPA.
• the term “amount” herein relates to weight or volume of the fatty acid composition .
• the desired pharmacological and/or therapeutic effect may be achieved by the fatty acid composition according to the invention .
• EPA and DHA in the fatty acid composition are present in the composition of an EPA r DHA ratio from 1 : 1 to 1 : 8. In a more preferred embodiment the EPA: DHA ratio in the fatty acid composition is from about 1 : 1 to 1 : 6. In a specific embodiment of the invention, the fatty acid composition is a DHA-product .
• the fatty acids in the composition according to the invention is presented in at least one of esterified form, ethyl ester form, salt form and free acid form, or any combinations thereof .
• the fatty acid composition is comprised of a combination of EPA and DHA in triglyceride form.
• At least DHA is obtained from at least one of vegetable , microbial and animal origins , or combinations thereof .
• the fatty acid composition comprising at least a combination of DHA and EPA
• at least one of DHA and EPA is obtained from at least one of vegetable , microbial and animal origins or combinations thereof .
• the food stuff or food supplement includes therefore, for instance , a fatty acid composition comprising at least one of a DHA-containing microbial oil and a mixture of an DHA-containing oil from microbial origin and a EPA- containing oil from a marine origin .
• the fatty acid composition according to the invention may additionally also comprise at least one of arachidonic acid (ARA) , docosapentaenoic acid, heneicosapentaenoic acid and octadecatentraenoic or derivatives thereof, or any combinations thereof .
• ARA arachidonic acid
• the EPA and/or DHA is produced from a marine oil , preferably a fish oil .
• the fatty acid composition is produced from a marine oil , such as a fish oil .
• the fatty acid composition is comprised of at least a combination of EPA and DHA in triglyceride form.
• the fatty acid composition is administered to a human or an animal , preferably orally .
• the food stuff or food supplement according to the invention may also be produced for administration though any other route as mentioned before .
• the food stuff or food supplement is in form of a capsule .
• the capsule is flavoured . More preferably, the capsule is a gelatine capsule which is flavoured .
• This embodiment also includes a capsule, therein both the capsules and the encapsulated fatty acid composition are flavoured. By flavouring the capsule as mentioned above, the capsule becomes more attractive to the user .
• said fatty acid composition is administered in an amount providing a daily dosage of 1 g to 15 g of said fatty acid composition for a human . In a more preferred embodiment between 2 and 10 g of said fatty acid composition is administered per day, and in a most preferred embodiment between 2 and 8 g of said fatty acid composition .
• the food stuff or food supplement according to the invention may also comprise other substances such as an inert vehicle , or pharmaceutical acceptable adj uvants , carriers , preservatives etc . , which are well known in to those skilled in the art . Additionally, even the food stuff or food supplement may be administered to an animal such as a pet or a horse . Moreover, it should be pointed out that the food stuff or food supplement may be at least one of an amyloid-preventing agent or amyloid- deposit decreasing agent .
• the present invention relates to use of a fatty acid composition comprising at least (all-Z omega-3 ) -4 , 7 , 10, 13 , 16, 19-docosahexaenoic acid ( DHA) , that upon administration to a human or an animal will prevent the formation of aggregates of protein fibrils or plaque and/or reduce deposed fibrils , for the production of a medicinal product for the treatment and/or prevention of amyloidos-related diseases .
• said amyloidos-related disease is Alzheimer' s dementia or Alzheimer' s disease .
• the term Alzheimer' s also includes persons who are at risk of, or exhibits the symptoms of Alzheimer' s disease .
• one advantage of selling a food stuff for prevention of preferably Alzheimer' s disease or Parkinson' s disease is that the food stuff may help people not to develop these diseases in the future .
• said amyloidos-related disease is IgA nephropathy .
• a fatty acid composition comprising a combination of at least DHA and EPA is used for the treatment and/or prevention of IgA nephropathy .
• the invention also includes use of a fatty acid composition comprising an effective amount of at least DHA or a combination of EPA or DHA, that upon administration to a human or an animal preferable will prevent the formation of aggregates of protein fibrils or plaque and/or reduce deposed fibrils , for the production of a food stuff or food supplement for the treatment and/or prevention of IgA nephropathy .
• the invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3 ) -4 , 7 , 10 , 13 , 16, 19- docosahexaenoic acid ( DHA) for the production of a food stuff or food supplement for the treatment and/or prevention of amyloidos-related diseases , wherein the disease is type II diabetes mellitus .
• said fatty acid composition further comprises ( all-Z omega-3 ) -5 , 8 , 11 , 14 , 17-eicosapentaenoic acid (EPA) , i . e . the fatty acid composition comprising at least a combination of EPA and DHA, for treatment of type II diabetes .
• the amount of DHA > EPA.
• amyloidos-related diseases is at least one of amyloidoses , Parkinson' s disease, amyotrophic lateral sclerosis , the spongiform encephalopathies such as Creutzfeld-Jacob disease, cystic fibrosis , kidney amyloidoses secondary to inflammatory diseases , renal amyloidoses , and amyloid deposition in myocardium and neural tissue .
• the present invention relates to a method for the treatment and/or prevention of amyloidos-related diseases , wherein an effective amount of a fatty acid composition comprising at least ( all-Z omega-3 ) -4 , 7 , 10 , 13 , 16, 19- docosahexaenoic acid ( DHA) is administered to a human or an animal .
• an effective amount also includes a therapeutically or a pharmaceutically active amount of the fatty acid composition . This expression relates to a dose of said fatty acid composition that will lead to the desired pharmacological and/or therapeutic effect .
• the desired pharmacological and/or therapeutic effect is , as stated above, achieved by the fatty acid composition according to the invention .
• a fatty acid composition according to the invention prevents formation of so called fibrils or plaques , and/or reduces deposed fibrils or plaques , known as amyloid .
• the fatty acid composition further comprises (all-Z omega-3 ) - 5 , 8 , 11 , 14 , 17-eicosapentaenoic acid (EPA) .
• the weight ratio of EPAi DHA in the fatty acid composition is 1 : X, where X is equal or greater than 1.
• the most preferred effect of the invention is also here accomplished by the use of at least DHA or a fatty acid composition rich in DHA .
• a fatty acid composition containing at least a combination of the two fatty acids DHA and EPA also demonstrates preventive effect against fibril formation .
• the method leads to the same advantages and possibilities as mentioned before .
• amyloidos-related diseases such as Alzheimer' s disease, IgA nephropathy, type II diabetes mellitus , amyloidoses , Parkinson' s disease, kidney amyloidoses secondary to chronic inflammatory disease and Creutzfeld-Jacob disease .
• the invention relates to a method for treatment and/or prevention of Alzheimer' s disease, wherein a fatty acid composition comprising at least a combination of (all-Z omega-3 ) -5, 8 , 11 , 14 , 17-eicosapentaenoic acid (EPA) and
• DHA 19-docosahexaenoic acid
• the disease is caused by deposition of amyloid .
• the method of treating Alzheimer' s disease is related to administering to a human suffering from the disease an effective Alzheimer' s disease alleviating amount of a amyloid-deposit-decreasing agent .
• the amyloid-deposit-decreasing agent is a fatty acid composition comprising at least one of a combination of the fatty acids DHA and EPA .
• the embodiment relates to use of a fatty acid composition comprising at least a combination of DHA and EPA, that upon administration to a human or an animal will lead to prevention of, or reduction of, deposition of amyloid, for the manufacture of a medicament or a food supplement, for the treatment and/or prevention of Alzheimer' s disease, preferably caused by amyloidosis .
• the fatty acid composition comprising at least 70% unsaturated omega-3 fatty acids wherein the fatty acids DHA and EPA are present in a weight ratio from about 1 : 2 to 2 : 1.
• the invention relates to the use of a fatty acid composition, wherein the weight ratio of EPA: DHA in the fatty acid composition is 1 : X, where X is equal or greater than 1. Please note that X being one of an integer or non-integer .
• a preferred effect of the invention is accomplished by a fatty acid composition rich in DHA.
• the term “rich” herein includes more or less a fatty acid composition primary containing DHA (none EPA) , , and a fatty acid composition where the amount of DHA > EPA.
• the term “amount” herein relates to weight or volume of the fatty acid composition .
• the desired pharmacological and/or therapeutic effect may be achieved by the fatty acid composition according to the invention .
• the fatty acids in the composition are presented in at least one of esterified form, ethyl ester form, salt form and free acid form, or any combinations thereof .
• the fatty acid composition is comprised of a combination of EPA and DHA in triglyceride form.
• at least one of DHA and EPA is obtained from at least one of vegetable, microbial and animal origins or combinations thereof .
• the medicinal product or pharmaceutical product includes therefore , for instance , a fatty acid composition comprising at least one of a DHA-containing microbial oil and a mixture of an DHA-containing oil from microbial origin and a EPA-containing oil from a marine origin .
• the fatty acid composition according to the invention may additionally also comprise at least one of arachidonic acid (ARA) , docosapentaenoic acid, heneicosapentaenoic acid and octadecatentraenoic, or any combinations thereof .
• ARA arachidonic acid
• at least a part of the EPA and/or DHA is produced from a marine oil , preferably a fish oil .
• the fatty acid composition is produced from a marine oil, such as a fish oil .
• the fatty acid composition is comprised of at least a combination of EPA and DHA in triglyceride form.
• the fatty acid composition is administered to a human or an animal, preferably orally.
• the fatty acid composition according to the invention may also be produced for administration though any other route where the active ingredients may be efficiently absorbed and utilized, e . g . intravenously, subcutaneously, intramuscularly, intranasally, rectally, vaginally or topically .
• said fatty acid composition is administered in an amount providing a daily dosage of 1 g to 15 g of said fatty acid composition for a human . In a more preferred embodiment between 2 and 10 g of said fatty acid composition is administered per day, and in a most preferred embodiment between 2 and 8 g of said fatty acid composition .
• the preparation according to the invention may also comprise other substances such as an inert vehicle, or pharmaceutical acceptable adj uvants , carriers , preservatives etc . , which are well known to those skilled in the art .
• the fatty acid mixture or composition may be at least one of an amyloid-preventing agent or amyloid- deposit decreasing agent .
• the invention also relates to a method for treatment of Alzheimer' s disease due to prevention of misfolding of proteins , or fragments , that may lead to formation of so called fibrils or plaques , and/or due to decreasing of amyloid deposits , wherein a fatty acid composition according to the invention is administered to a human .
• the invention relates to a method for prevention and/or for treatment of amyloidoses , wherein a fatty acid composition comprising at least (all-Z omega- 3 ) -4 , 7 , 10 , 13 , 16 , 19-docosahexaenoic ( DHA) is administered to a human or an animal .
• the fatty acid composition further comprises (all-Z omega-3 ) - 5 , 8 , 11 , 14 , 17-eicosapentaenoic acid (EPA) .
• the weight ratio of EPA: DHA in the fatty acid composition is 1 : X, where X is equal or greater than 1. From the research leading to the invention it was found that the most preferred effect concerning inhibitation, or prevention, of formation of fibril aggregates is accomplished by a fatty acid composition comprising at least DHA .
• a fatty acid composition comprising at least DHA and EPA, wherein the amount of DHA > EPA, also show preventive effect against fibril formation .
• the invention also includes use of a fatty acid composition comprising at least DHA preferable at least a combination of DHA and EPA, for prevention of fibrils , plaque, or amyloid aggregates .
• amyloidos-related conditions or diseases at least includes Alzheimer' s disease or dementia, Parkinson' s disease, amyotrophic lateral sclerosis , the spongiform encephalopathies such as Creutzfeld-Jacob disease, cystic fibrosis , type II diabetes , renal amyloidoses , IgA nephropaty, and amyloid deposition in myocardium and neural tissue .
• These diseases can be sporadic, inherited or even infectious , and are often occur only late in life even if inherited forms may appear much earlier .
• Each disease is associated with a particular protein and aggregates of these proteins are thought to be the direct origin of the pathological conditions associated with the disease .
• the treatment and/or prevention according to administering the fatty acid composition of the invention may also include at least one of; treatment due to reduction of amyloid aggregates, prevention of misfolding of proteins that may lead to formation of so called fibrils or plaque, treatment due to decreasing of the production of A ⁇ -protein ( amyloid beta protein) , and prevention and/or treatment due to inhibiting or slow down the formation of protein fibrils , aggregates , or plaque .
• the present invention also includes prevention of fibril accumulation, or formation, by administering a fatty acid composition according to the invention .
• treatment means both treatment having a curing or alleviating purpose and the treatment of a amyloidos-related disease can be made either acutely or chronically .
• chronically treatment is meant a treatment witch continues for weeks or years .
• Fig 1 shows fibril formation of omega-3 preparations during 30 minutes .
• Figure 2 demonstrates fibril formation between the fatty acid preparations with the most prominent fibril inducing effect, soy oil and olive oil , compared to the fibril preventing DHA-concentrate EPAX 2050 (which comprises approximately 20% EPA and 50% DHA) .
• figure 3 shows preventive effect against fibril formation up to at least 150 minutes comparing different omega-3 preparations .
• Figure 4 illustrates effects against fibril formation with a DHA-concentrate compared to olive oil and soy oil .
• a number of preferred embodiments of the invention were performed in order to demonstrate that a fatty acid composition rich in DHA is effective on the treatment and/or prevention of amyloidos-related diseases .
• Fibril formation is a consequence of misfolding the precursor proteins .
• the reason for this abnormal behaviour of forming normal three-dimensional structures has not been fully elucidated.
• the present invention discloses the results of experiments with one synthetic precursor protein, synthetic IAPP, spontaneously forming fibrils , as well as semi-vivo experiments with pancreatic islets from transgenic animals producing human IAPP .
• the invention also discloses results from in vivo experiments in animals where organ amyloid is induced by inj ections of a pro-inflammatory compound, namely silver nitrate .
• This peptide was incubated with free fatty acids of marine origin comparing the effects on fibril formation with fatty acids like oleic acid and linoleic acid known to stimulate the formation of amyloid fibrils .
• the present invention also discloses results of experiments in a semi-vivo model, where pancreatic islets from transgenic mice producing human IAPP and spontaneously forming beta-call amyloid were prepared and incubated with oleic acid and docosahexaenoic acid . It is well established that inflammatory diseases create a high risk of developing amyloid in different organs , a situation called secondary amyloid . A situation of extreme inflammation was created in mice inj ected weekly with silver nitrate . Different groups of animals were treated with EPAX 1050 (a high DHA omega-3 oil) , pure DHA ( 97% concentrate) , or olive oil (containing about 80% oleic acid) . A control group was given standard chow .
• a fatty acid composition rich in DHA EPAX 2050 (a high omega-3 oil) , an oil comprising at least a combination of DHA and EPA,
• Synthetic precursor protein synthetic IAPP spontaneously forming filbrils
• DMSO dimethylsulfoxide
• 25 ⁇ M was incubated with each one of the fatty acids , each one in a concentration of 125 ⁇ M, in distilled water .
• One ⁇ l aliquots of each sample were analysed after 5 , 10 , 20 , 30 , 60 , 90 , 120 , 150 , 180 , 210 , and 240 minutes in the electron microscope after negative contrasting with 2% uranyl acetate in 50% ethanol .
• FIG. 1 demonstrates fibril formation of the omega-3 preparations during 30 minutes .
• the omega-3 concentrate containing predominantly DHA, EPAX 2050 seemed to prevent or delay the spontaneously formation of fibrils most effectively.
• figure 2 demonstrates fibril formation between the fatty acid preparation with the most prominent fibril inducing effect, olive oil and soy oil , compared to the fibril preventing DHA-concentrate EPAX 2050.
• fibril induction was also followed for 240 minutes to quantify the fibril preventive effect of the DHA-concentrate .
• Figure 3 demonstrates that preventive effect against fibril formation was evident up till 150 minutes in the experiment comparing different omega-3 preparations . Similar prevention was obtained in the experiment with the DHA concentrate compared to olive oil and soy oil, see figure 4.
• this study shows that treatment with a fatty acid composition rich in DHA leads to prevention of fibril or plaque formation . Moreover, it seams that DHA act as an fibril inhibitor . At the same time the invention also shows preventive effect on fibril formation of a product comprising at least a combination of DHA and EPA, wherein preferably the amount of DHA > EPA. The results also suggest a specific preventive effect against fibril formation of an omega-3 product of marine origin as compared with soy oil and olive oil .
• Transgenic mice carrying the human IAPP gene may be used for studying deposition of amyloid fibrils in the pancreatic islets ( 11 ) . Therefore , single pancreatic islets were isolated and cultured from transgenic mice .
• Pancreas were removed under sterile conditions and placed in Hank' s balanced salts and finely minced . Small pieces of tissue were enzymatically digested by collagenase for
• mice Female NMRI mice were inj ected once a week subcutaneously with 0.3 ml of a 1% silver nitrate solution for 25 weeks .
• the animals were fed high fat diet containing mainly sunflower oil with a fat content of 55% of total daily calories .
• Three groups each consisting of 6 animals were given different omega-3 fatty acid concentrates ( intervention group) or standard olive oil containing about 78% oleic acid (oleic acid group) .
• intervention groups 15% of the fat content was exchanged with either 97% docosahexaenoic acid ( DHA group) or EPAX1050TG containing 10% of EPA and 50% of DHA (EPAX group) .
• mice were sacrificed and spleens were collected.
• amyloid demonstration one half of each spleen was crushed between two glass slides , smeared homogenously over both slides , and air-dried in room temperature overnight , while the other half of the spleen was fixed in 10% buffered neutral formalin solution and embedded in paraffin .
• the air-dried smear material and 10- ⁇ m-thick sections from the formalin fixed material were stained for amyloid with specific dye alkaline Congo red .
• the slides were examined in cross-polarized light for bright green birefringence, specific for amyloid . Evaluation of the material was performed on coded slides .
• Amyloid appeared in the spleen in three out of five mice fed oleic acid, in one out of six mice fed DHA and in one out of five mice fed EPAX (table below) . Two animals died during the study .
• the invention also shows preventive effect on fibril formation of a product comprising at least a combination of DHA and EPA, wherein preferably the amount of DHA > EPA.
• a preventive effect of amyloid deposition could even be demonstrated in vivo by giving animals with silver nitrate induced secondary amyloidoses different fatty acids or fatty acid combination .
• After 25 weeks of treatment animals given EPAX1050 or approximately pure DHA did not develop amyloid to the same extent as animals given oleic acid .
• only one animal in the DHA groups (EPAX1050 and pure DHA) developed amyloid after silver nitrate inj ections compared to 3 animals in the oleic acid group . Even if the number of animals used is too small for a statistical evaluation, the trend is quite clear meaning that DHA or high DHA concentrates seems to prevent against development of amyloid.

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Diabetes (AREA)
• Emergency Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Psychiatry (AREA)
• Psychology (AREA)
• Endocrinology (AREA)
• Urology & Nephrology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicinal Preparation (AREA)

Priority Applications (6)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=36692011

Family Applications (1)

Country Status (7)

Cited By (9)

Families Citing this family (4)

Citations (3)

Family Cites Families (11)

• 2006
  • 2006-01-24 WO PCT/IB2006/000106 patent/WO2006077495A1/en not_active Ceased
  • 2006-01-24 CA CA002594781A patent/CA2594781A1/en not_active Abandoned
  • 2006-01-24 JP JP2007551765A patent/JP5503846B2/ja not_active Expired - Fee Related
  • 2006-01-24 US US11/795,800 patent/US20090054523A1/en not_active Abandoned
  • 2006-01-24 EP EP06710253A patent/EP1845999A4/en not_active Withdrawn
• 2007
  • 2007-08-22 KR KR20077019198A patent/KR101253696B1/ko not_active Expired - Fee Related
  • 2007-08-23 NO NO20074318A patent/NO343234B1/no not_active IP Right Cessation
• 2012
  • 2012-06-21 US US13/529,592 patent/US20120277317A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events